loading
전일 마감가:
$56.45
열려 있는:
$56.49
하루 거래량:
502.18K
Relative Volume:
0.20
시가총액:
$6.87B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
18.44
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-3.24%
1개월 성능:
+5.62%
6개월 성능:
-0.29%
1년 성능:
+3.22%
1일 변동 폭
Value
$55.72
$56.66
1주일 범위
Value
$55.75
$58.56
52주 변동 폭
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
명칭
Halozyme Therapeutics Inc
Name
전화
(858) 794-8889
Name
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
직원
350
Name
트위터
@halozymeinc
Name
다음 수익 날짜
2025-02-18
Name
최신 SEC 제출 서류
Name
HALO's Discussions on Twitter

HALO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
HALO
Halozyme Therapeutics Inc
55.72 7.10B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.50 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.49 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.13 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
567.20 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
290.51 27.29B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-10 재개 Goldman Neutral
2025-05-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2025-05-13 다운그레이드 Leerink Partners Market Perform → Underperform
2024-10-07 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-09-19 다운그레이드 JP Morgan Overweight → Neutral
2024-06-07 다운그레이드 Piper Sandler Overweight → Neutral
2024-02-29 개시 TD Cowen Outperform
2023-07-24 다운그레이드 Goldman Buy → Neutral
2023-07-24 개시 H.C. Wainwright Buy
2023-05-10 업그레이드 Piper Sandler Neutral → Overweight
2023-03-27 재개 Berenberg Buy
2023-03-16 다운그레이드 SVB Securities Outperform → Market Perform
2022-12-21 재개 Morgan Stanley Overweight
2022-11-28 개시 Wells Fargo Overweight
2022-09-09 개시 Morgan Stanley Overweight
2022-05-23 개시 SVB Leerink Outperform
2021-06-14 개시 Evercore ISI Outperform
2021-05-17 개시 SVB Leerink Outperform
2021-05-11 다운그레이드 Piper Sandler Overweight → Neutral
2021-01-21 재확인 The Benchmark Company Buy
2020-12-17 개시 Berenberg Buy
2020-09-14 재개 JP Morgan Overweight
2020-07-01 개시 The Benchmark Company Buy
2020-02-05 업그레이드 Piper Sandler Neutral → Overweight
2020-01-09 업그레이드 BMO Capital Markets Market Perform → Outperform
2020-01-08 개시 Goldman Buy
2019-11-05 업그레이드 Barclays Underweight → Equal Weight
2018-10-19 재개 Piper Jaffray Neutral
2018-05-11 다운그레이드 Barclays Equal Weight → Underweight
2018-01-24 개시 Goldman Neutral
2017-10-16 재확인 Piper Jaffray Overweight
2017-01-06 다운그레이드 Citigroup Buy → Neutral
2016-11-03 개시 Deutsche Bank Buy
2015-12-04 개시 Wells Fargo Outperform
2015-11-18 개시 Citigroup Buy
2015-09-22 개시 Barclays Overweight
2015-06-22 재확인 JP Morgan Overweight
2015-03-03 재확인 UBS Buy
2015-02-18 재확인 MLV & Co Buy
2015-01-08 재확인 MLV & Co Buy
모두보기

Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스

pulisher
08:30 AM

What analysts say about Halozyme Therapeutics Inc. stockConsistent high-yield stocks - jammulinksnews.com

08:30 AM
pulisher
Jul 20, 2025

Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Halozyme Therapeutics Inc. stock priceExplosive capital gains - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Halozyme Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Beginners Guide - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 13:49:29 - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 17, 2025

Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat

Jul 16, 2025
pulisher
Jul 16, 2025

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru

Jul 16, 2025
pulisher
Jul 16, 2025

Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Halozyme Therapeutics' strategic adoption - MarketScreener

Jul 16, 2025
pulisher
Jul 14, 2025

Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 11, 2025

Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus

Jul 10, 2025
pulisher
Jul 07, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga

Jul 07, 2025
pulisher
Jul 06, 2025

Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress

Jul 06, 2025
pulisher
Jul 04, 2025

Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN

Jul 04, 2025
pulisher
Jul 04, 2025

Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 03, 2025
pulisher
Jul 01, 2025

Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa

Jun 30, 2025
pulisher
Jun 30, 2025

Halozyme therapeutics added to Russell 1000 index - Investing.com

Jun 30, 2025
pulisher
Jun 21, 2025

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve

Jun 21, 2025
pulisher
Jun 20, 2025

Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan

Jun 20, 2025
pulisher
Jun 18, 2025

Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st

Jun 18, 2025
pulisher
Jun 16, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance

Jun 16, 2025
pulisher
Jun 15, 2025

Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha

Jun 15, 2025
pulisher
Jun 12, 2025

Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Merck gains U.S. patent office support in Keytruda dispute - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025

Halozyme Therapeutics Inc (HALO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Torley Helen
PRESIDENT AND CEO
Jul 09 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jul 10 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jul 10 '25
Sale
57.43
20,000
1,148,618
733,719
Torley Helen
PRESIDENT AND CEO
Jul 09 '25
Sale
56.43
20,000
1,128,655
733,719
Torley Helen
PRESIDENT AND CEO
Jul 08 '25
Sale
55.51
20,000
1,110,245
733,719
Torley Helen
PRESIDENT AND CEO
Jun 20 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jun 24 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jun 23 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jun 24 '25
Sale
53.73
20,000
1,074,620
733,719
Torley Helen
PRESIDENT AND CEO
Jun 20 '25
Sale
52.96
20,000
1,059,200
733,719
$21.67
price down icon 1.03%
$35.60
price up icon 0.17%
$102.58
price down icon 0.03%
$26.88
price up icon 1.05%
$110.44
price down icon 0.20%
biotechnology ONC
$290.46
price down icon 1.81%
자본화:     |  볼륨(24시간):